| Literature DB >> 35879589 |
Yuan-Kai Song1,2,3,4, Hao-Xiang Yuan1,2,3,4, Yu-Peng Jian1,2,3,4, Ya-Ting Chen1,2,3,4, Kai-Feng Liang1,2,3,4, Xiao-Jun Liu1,2,3,4, Zhi-Jun Ou2,3,4,5, Jia-Sheng Liu1,2,3,4, Yan Li6,7,8,9, Jing-Song Ou10,11,12,13,14.
Abstract
The aim of this study was to investigate whether pentraxin 3 (PTX3) in microvesicles (MVs) can be a valuable biomarker for the prediction of acute heart failure (AHF) after cardiac surgery with cardiopulmonary bypass (CPB). One hundred and twenty-four patients undergoing cardiac surgery with CPB were included and analyzed (29 with AHF and 95 without AHF). The concentrations of PTX3 in MVs isolated from plasma were measured by ELISA kits before, 12 h, and 3 days after surgery. Patients' demographics, medical history, surgical data, and laboratory results were collected. The levels of PTX3 in MVs were significantly elevated during perioperative surgery, which was increased more in the AHF group. The concentrations of PTX3 in MVs at postoperative 12 h were independent risk factors for AHF with the area under the ROC curve of 0.920. The concentration of PTX3 in MVs may be a novel biomarker for prediction of AHF after cardiac surgery.Entities:
Keywords: Acute heart failure; Biomarker; Cardiopulmonary bypass; Microvesicles; Pentraxin 3
Year: 2022 PMID： 35879589 DOI： 10.1007/s12265-022-10253-w
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN： 1937-5387 Impact factor: 3.216